Conclusion Robotic multiplex partial nephrectomy is a safe and feasible approach to patients with multifocal renal masses. These complex surgeries have a demonstrated learning curve, but this minimally invasive approach for nephron-sparing surgery allows patients to preserve renal function where they would otherwise require open surgery or a radical nephrectomy.
Introduction
Robotic surgery has enabled expansion of minimally invasive surgery that was previously prohibitively difficult with standard laparoscopy. Robotic partial nephrectomy is a well-established technique in the management of renal cell carcinoma (RCC) that is used more frequently for complex multifocal disease [1, 2] . We manage a large population of patients with hereditary and multifocal renal cell carcinoma conditions. Surgical treatment with partial nephrectomy remains the standard of care for most hereditary renal cancers when the largest renal mass approaches 3 cm [3] . As our experience with robotic partial nephrectomy has increased, we have applied this technique to increasingly complex renal tumors as well as increasing numbers of tumors [4] [5] [6] [7] [8] [9] [10] . Herein, we present renal functional outcomes after robotic surgery on a single kidney with more than three masses, which we have termed a "robotic multiplex partial nephrectomy" (RMxPNx). Multiplex is defined as "consisting of many elements in a complex relationship" which accurately describes the unique challenges presented by multifocal tumors in a single kidney (http://www.
Abstract
Objective To identify renal function outcomes after robotic multiplex partial nephrectomy (RMxPNx), we reviewed our institutional database at the National Institutes of Health, National Cancer Institute. To our knowledge, we present the largest series of RMxPNx renal function outcomes to date. Robotic partial nephrectomy has been employed for oncologic control and to prevent dialysis dependence in hereditary multifocal renal cell carcinoma conditions. We have termed robotic surgery on a single kidney with three or more lesions a RMxPNx.
Materials and methods
We evaluated patients from a prospectively maintained database at a single institution (NIH/ NCI) that underwent RMxPNx from 2007 to 2013. Demographic and operative data were compiled with statistical analysis with T test performed to determine renal function outcomes. Results A total of 54 patients underwent RMxPNx. Mean number of tumors removed was 8.63 (range 3-52). Mean preoperative creatinine and eGFR were 1.02 ± 0.26 mg/dL and 85.4 ± 21.5 mL/min, respectively. Postoperatively, creatinine increased from baseline by 0.45 mg/dL (p < 0.001). Similarly, a mean decrease in eGFR by 24.6 mL/min was observed (p < 0.001). At 3-month follow-up, the creatinine increase from baseline was 0.05 mg/dL (p = 0.10) and mean decrease in eGFR was 3.01 mL/min (p = 0.21). When stratifying based on preoperative CKD stages I-III, similar results were observed. 
Methods
Between January 2007 and November 2013, three surgeons (ARM, GB and PP) performed resection of 3 or more masses in a single kidney (RMxPNx). Tumors are resected using enucleation and renorrhaphy techniques as previously described [2] . Intraoperative ultrasound was used to identify endophytic tumors, and resection was performed on smaller, exophytic masses before more complex tumors were removed. Data compiled included age, gender, demographics, number of previous abdominal surgeries, laterality, number of tumors, operative time, preoperative (pre-op) serum creatinine (SCr) and postoperative (post-op) SCr daily and at 3-month postoperative follow-up. Renal function was additionally assessed using eGFR (CKD-EPICreatinine 2009 formula), and differences were reported as percent change in eGFR from preoperative value. Renal function outcomes were further stratified based on CKD stages I, II and III. Differences in SCr, eGFR and clinical variables were compared using logistic regression, Spearman rank correlations and T test.
Results
A total of 407 partial nephrectomies were performed at the NIH from 2007 to 2013. One hundred and twenty-one underwent robotic renal surgery, and of these, 54 patients underwent RMxPNx (mean age 46, range 20-84). All RMxPNx cases performed at NIH have been included in this study and were performed transperitoneally. Table 1 summarizes the demographic data for these patients. Sixtysix percent were male and 83 % were Caucasian. Mean body mass index (BMI) was 30.5 (range 22.5-41.6), and mean ASA at surgery was 3.0 (range 2-3). Operative characteristics are presented in Table 2 . The mean number of previous abdominal surgery patients who had undergone prior to the RMxPNx was 0.63 ± 0.8, with as many as 3 previous abdominal surgeries in the same patient. No laterality was predominant with 54 % RMxPNx performed on the right versus 46 % performed on the left. The mean number of tumors removed was 8.63 (mode 3.0). Operative time averaged 382 min (6.4 h), which included routine cystoscopy and ipsilateral ureteral catheter placement in addition to the minimally invasive renal surgery. Estimated blood loss averaged 1439 mL (range 250-8500 mL) with 79 % of patients undergoing a blood transfusion intraoperatively. Renal hilar occlusion was performed for masses concerning for increased hemorrhage due to preoperative imaging and intraoperative judgment in only 10 of the 54 cases with a mean warm ischemia time of 23.3 min (Table 2) .
Six cases (11 %) were converted to open partial nephrectomy. Only 1 case was converted to open after 2010 for a Renal vascular injury 1 (1.8 %) (radical nx) conversion rate of 2.7 % during the latter part of the series, and no robotic to open conversions occurred in the last 33 cases of the series. Reasons for conversion included endophytic lesions deemed by the operating surgeon at the time unsafe to be removed robotically, adhesions and renal vascular injury. Only one case was converted from robotic MxPNx to radical nephrectomy for a renal vascular injury sustained intraoperatively. Mean preoperative SCr and eGFR were 1.02 ± 0.26 mg/ dL and 85.4 ± 21.5 mL/min, respectively (Table 3) . Perioperatively, the mean SCr increased to 1.47 ± 0.53 mg/ dL (p = 0.016) and eGFR diminished to 60.8 ± 24.3 mL/ min (p = 0.031). At 3-month post-op follow-up, the mean SCr was 1.07 ± 0.33 mg/dL, an increase of 0.05 mg/dL (p = 0.101) from baseline. Mean eGFR at 3-month follow-up was 82.3 ± 23.9 mL/min, a decrease from baseline of 3.1 mL/min (p = 0.21) (Fig. 1) . Perioperatively, SCr increased 23.8 % (p = 0.016) from baseline but reduced to a 4.9 % increase in SCr at 3-month follow-up (p = 0.10). The overall eGFR declined by 28.8 % (p = 0.03) in the perioperative period but by only 3.6 % (p = 0.21) at 3-month follow-up (Table 3) .
Number of tumors removed and EBL did not correlate with change in SCr, eGFR at discharge or 3-month post-op follow-up. Longer surgery time was positively correlated with SCr (r = 0.31) and negatively correlated with eGFR (r = −0.3) at 3-month follow-up.
Patients were further sub-categorized based on stages of preoperative CKD. Patients with preoperative eGFR <60 mL/min demonstrated a 37 % decrease in eGFR at discharge (p = 0.02); however, at 3-month follow-up, patients with stage III CKD were found to have only decreased eGFR 10 % (p = 0.25), which did not achieve statistical significance.
Discussion
Urologic surgeons continue to perform more complex surgeries using robotic techniques since its introduction in 2000s. Previous studies show that laparoscopic partial nephrectomy and robotic partial nephrectomy result in less blood loss and shorter recovery with similar longterm renal function and oncologic outcomes [1, 3-5, 8, 10] . Patients with multiple complex renal masses often have bilateral disease, and the previous standard of radical nephrectomy would leave these patients on renal replacement therapy [4] . Cr post-op peak 1.47 ± 0.53 p < 0.016 eGFR post-op nadir 60.8 ± 24.3 p < 0.031
Cr at 3-month follow-up 1.07 ± 0.33 p = 0.101 eGFR 3-month follow-up 82.3 ± 24.0 p = 0.21 Fig. 1 Preoperative, postoperative and 3-month follow-up trends for serum creatinine and eGFR
Our findings demonstrate that the RMxPNx preserves renal function for multitumor partial nephrectomy. No statistically significant changes in either SCr or eGFR were observed over the study period that included both primary partial nephrectomies as well as reoperative RMxPNx. During the seven-year study period, the robotic to open conversion rate decreased by more than threefold in the first three years (Fig. 2) . The mean number of tumors removed during each case also steadily increased over that same time period, likely representing improvement in surgical skill and technique as experience increased.
Given the concern for prolonged ischemia times or the need for repeated hilar occlusion in this patient population, hilar occlusion is rarely performed except for the most endophytic masses or those intimately associated with the vasculature seen on preoperative imaging. This may contribute to the notable preservation of renal function seen in this series of RMxPNx. Additionally, our enucleation technique also allows for maximal preservation of unaffected renal parenchyma, a primary predictor of postoperative renal function [13, 14] . As a result of the off-clamp approach to most of these tumors, the estimated blood loss in this series is markedly higher than in other published reports of robotic partial nephrectomy [10] .
Preservation of renal function despite preoperative renal dysfunction was also observed in this cohort. Stratified by CKD stage, an acute decline in renal function was observed irrespective of preoperative eGFR. In patients with preoperative stage III CKD, a 10 % decrease in eGFR was seen at follow-up, but this did not achieve statistical significance. This is likely due to the current sample size and will delineate itself with further statistical analysis as more RMxPNx cases accrue.
Given excellent renal function preservation demonstrated by standard measures, volume-adjusted functional outcomes and differential renal function by radio-nucleotide imaging were deemed unnecessary. More important will be longer follow-up to determine long-term renal function outcomes in this patient population that is at increased risk of needing subsequent renal surgeries.
Although oncologic outcomes are not the focus of this article, overall survival and cancer-specific survival were 100 % at last follow-up. The durability of surgical excision was not determined due to high risk of local recurrence with hereditary kidney cancers.
Although this study is the largest of its kind to date, limitations exist regarding the sample size and retrospective nature of the study. We utilize the 3-cm approach described by Duffey et al. [15] as the cutoff for surgical intervention. The vast majority of the patients in our cohort had at least one mass that was approaching 3 cm at the time of surgery. The remaining masses removed from the kidneys were typically less than 1-1.5 cm each. Pathologic margin status is also not reported, given the technique of enucleation performed on these masses; however, to this date no cases of metastatic disease has been recorded if patients undergo partial nephrectomy before the renal mass grows larger than 3 cm [15] . This study also does not compare robotic assistance to other approaches for partial nephrectomy; rather, it presents a feasible technique for a minimally invasive approach to management of multiple renal tumors.
Conclusion
Robotic partial nephrectomy for 3 or more tumors in a single kidney is safe and feasible in selected patients. More importantly, these data demonstrate exceptional renal function preservation despite the highly challenging nature of this type of surgery.
